Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

▤ Summary

Immatics shared new Phase 1 data for IMA401 at ASCO and in Nature Medicine. The results show encouraging anti-tumor activity, including a 29% confirmed response rate in head and neck cancer and a durable response signal in melanoma. The company also reported favorable tolerability, including no ICANS and manageable adverse events at the recommended Phase 2 dose. Immatics has started enrollment for an IMA401 plus IMA402 combination cohort in squamous cell non-small cell lung cancer and expects first data in 2027. The update reinforces the company’s strategy around its TCR bispecific platform and broader PRAME-focused pipeline.

▦ Linked Companies